ICAM1 and neoplasm: We found that I domain CARs exhibiting affinities in the micromolar range (~10 μM) exhibited a significantly higher therapeutic index in vivo compared to CARs with higher affinity (1–100 nM) which tended to cause unbiased reactivity against normal cells with basal ICAM-1 expression and led to less efficient tumor regression.